Savara (SVRA) Non-Current Assets (2010 - 2026)
Savara (SVRA) posted quarterly Non-Current Assets of $12.4 million for Q1 2026, up 4.28% year-over-year from $11.9 million in Q1 2025, and up 4.74% quarter-over-quarter from $11.8 million in Q4 2025.
Savara (SVRA) Non-Current Assets (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Non-Current Assets for 17 consecutive years, with $12.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 4.28% year-over-year to $12.4 million; the TTM figure through Mar 2026 stood at $49.7 million (up 5.72% YoY), while the FY2025 annual figure was $11.8 million, up 10.01% from the prior year.
- Non-Current Assets advanced to $12.4 million in Q1 2026 per SVRA's latest filing, from $11.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.8 million in Q2 2025 and bottomed at $10.7 million in Q3 2022.
- Historically, Non-Current Assets has averaged $11.8 million across 5 years, with a median of $11.9 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 15.77% — and 2023, when it rose 12.04%.
- Savara's Non-Current Assets stood at $10.8 million in 2022, then climbed by 7.34% to $11.6 million in 2023, then retreated by 7.51% to $10.7 million in 2024, then rose by 10.01% to $11.8 million in 2025, then rose by 4.74% to $12.4 million in 2026.
- Business Quant data shows SVRA's Non-Current Assets at $12.4 million in Q1 2026, $11.8 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 13.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.82 Mn |
| Mar 31, 2026 | 12.38 Mn |
| Dec 31, 2025 | 11.82 Mn |
| Sep 30, 2025 | 12.73 Mn |
| Jun 30, 2025 | 12.78 Mn |
| Mar 31, 2025 | 11.87 Mn |
| Dec 31, 2024 | 10.74 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | 11.98 Mn |
| Mar 31, 2024 | 12.11 Mn |
| Dec 31, 2023 | 11.62 Mn |
| Sep 30, 2023 | 11.98 Mn |
| Jun 30, 2023 | 11.93 Mn |
| Mar 31, 2023 | 11.73 Mn |
| Dec 31, 2022 | 10.82 Mn |
| Sep 30, 2022 | 10.69 Mn |
| Jun 30, 2022 | 11.39 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 11.60 Mn |
| Sep 30, 2021 | 12.69 Mn |